![]() ![]() ![]() ![]() ![]() “It’s incredibly validating to the field,” says Nathaniel Wang, chief executive and co-founder of Replicate Bioscience in San Diego, California, a company that develops saRNA vaccines. “Being the first to bring an approval for this platform is pretty huge,” says Roberta Duncan, RNA-programme leader at CSL and vice-chair of the Alliance for mRNA Medicines, an advocacy organization that launched last month to advance the sector’s policy priorities. Researchers have been trying to make saRNA vaccines a reality for more than 20 years. When used as a booster in clinical testing, the newly authorized vaccine, ARCT-154 - developed by Arcturus Therapeutics in San Diego, California, and its partner CSL, a biotechnology firm headquartered in Melbourne, Australia - triggered higher levels of virus-fighting antibodies 1 that circulated the body for longer than did a standard mRNA COVID-19 vaccine. Why rings of RNA could be the next blockbuster drug And because it could be used at a lower dose, it might have fewer side effects than other messenger RNA (mRNA) treatments have. The new vaccine platform could provide potent defence against various infectious diseases and cancers. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells - the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world - marks a pivotal advance. The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. Credit: Pascal Pochard-Casabianca/AFP via Getty Self-amplifying RNA vaccines will add to the arsenal of conventional messenger RNA jabs. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |